Fulcrum Therapeutics Inc
NASDAQ:FULC
Fulcrum Therapeutics Inc
Cash from Financing Activities
Fulcrum Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
Cash from Financing Activities
$118.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
-$9.4B
|
CAGR 3-Years
-101%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fulcrum Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
118.1m
USD
Based on the financial report for Dec 31, 2023, Fulcrum Therapeutics Inc's Cash from Financing Activities amounts to 118.1m USD.
What is Fulcrum Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
2%
Over the last year, the Cash from Financing Activities growth was 40%. The average annual Cash from Financing Activities growth rates for Fulcrum Therapeutics Inc have been 18% over the past three years , 2% over the past five years .